AZUSA, Calif., Sept. 11 /PRNewswire-FirstCall/ -- Prior to embarking on a development program for VGV-1 in the United States, Viral Genetics (OTC Bulletin Board: VRAL - News) is initiating a comprehensive communications program to highlight key development milestones and promote awareness of the Company and its products. Based on the results of completed studies of VGV-1 in South Africa and elsewhere, Viral Genetics will move forward with the development of VGV-1 in the United States. VGV-1 is a suspension of thymus nuclear protein that has been tested in several studies in HIV infected individuals.
